期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 18, 页码 -出版社
MDPI
DOI: 10.3390/ijms21186885
关键词
osteosarcoma; chemoresistance; combination chemotherapy; drug synergy; methotrexate; doxorubicin; cisplatin; ifosfamide; tumour microenvironment; immunotherapy
资金
- Swedish Children's Cancer Foundation [PR2018-0016, TJ2019-0072]
- Swedish Cancer Society [CAN 2017/517]
- Stockholm County Council (ALF) [K2892-2016]
- Karolinska Institutet [2-2109/2019-18]
- Cancer Research Funds of Radiumhemmet [191112]
Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure. Introduction of combination chemotherapy in the 1970s, however, dramatically increased overall survival rates from 20% to approximately 70%. Unfortunately, large clinical trials aiming to intensify treatment in the past decades have failed to achieve higher cure rates. In this review, we revisit how the heterogenous nature of osteosarcoma as well as acquired and intrinsic resistance to chemotherapy can account for stagnation in therapy improvement. We summarise current osteosarcoma treatment strategies focusing on molecular determinants of treatment susceptibility and resistance. Understanding therapy susceptibility and resistance provides a basis for rational therapy betterment for both identifying patients that might be cured with less toxic interventions and targeting resistance mechanisms to sensitise resistant osteosarcoma to conventional therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据